Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757)

The Anti-DLL3 Antibody is derived from the anti-DLL3 arm of Tarlatamab (AMG-757), a bispecific T-cell engager (BiTE) that simultaneously targets DLL3 on tumor cells and CD3 on T cells. This monoclonal antibody is designed for precision in targeting the Delta-like ligand 3 (DLL3) protein, a promising therapeutic target in neuroendocrine tumors, including small cell lung cancer. The antibody's specificity for DLL3 makes it an invaluable tool for research focused on cancer biology and the development of targeted cancer therapies.